Physiomics Plc - Company Profile
Powered by 
All the data and insights you need on Physiomics Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Physiomics Plc Strategy Report
- Understand Physiomics Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Physiomics Plc (Physiomics) provides consulting services to pharmaceutical companies in the areas of computational biology and quantitative pharmacology. The company’s proprietary technology platform, Virtual Tumour, uses computer modeling to predict the effects of cancer drugs and treatments. Physiomics offers model-based drug development services, which include population (Pharmacokinetics and Pharmacodynamics) PKPD analysis of clinical data, back-translational analysis, and optimal design of future studies. It also has Quantitative Systems Pharmacology which involves the combination of PK/PD of a therapeutic agent with the mechanistic model and a large quantitative experimental drug data. Physiomics is headquartered in Oxfordshire, the UK.
Headquarters
United Kingdom
Address
Bee House, 140 Eastern Avenue, Milton Park, Oxford, England, OX144SB
Website
www.physiomics.co.uk
Telephone
44 1235 841575
No of Employees
10
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PYC (LON)
Revenue (2023)
$736,300
-28.1%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-88.5%
(2023 vs 2022)
Market Cap*
$2.5M
Net Profit Margin (2023)
XYZ
-162.1%
(2023 vs 2022)
* As of and is in US$
Products and Services
| Services | Brands |
|---|---|
| PK/PD Modelling | Virtual Tumour |
| Exposure Response Modelling | |
| Mechanism of Action Modelling | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company was awarded GBP125,000 contract with a new UK-based biotech client. |
| 2023 | Contracts/Agreements | In August, the company was awarded a contract by Merck KGaA. |
| 2023 | Contracts/Agreements | In August, the company was awarded a contract by Numab Therapeutics. |
Competitor Comparison
| Key Parameters | Physiomics Plc | Elekta AB | Avacta Group Plc | e-Therapeutics Plc | Cyprotex Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | Sweden | United Kingdom | United Kingdom | United Kingdom |
| City | Oxford | Stockholm | Wetherby | London | Nether Alderley |
| State/Province | England | - | England | England | Cheshire |
| No. of Employees | 10 | 4,541 | 120 | 38 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr. James Simon Millen | Chief Executive Officer | Executive Board | 2016 | 55 |
| Peter Sargent | Director; Chief Executive Officer | Executive Board | 2024 | - |
| Christophe Chassagnole | Director; Chief Scientific Officer | Executive Board | 2023 | 53 |
| Jim Millen | Chairman | Non Executive Board | 2024 | - |
| Hayley Close | Head - Business Development | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer